BICARA THERAPEUTICS INC (BCAX)
Health Care · biotechnology · NASDAQ
Bicara Therapeutics develops bifunctional, dual-targeting antibody therapies designed to penetrate and treat solid tumors by simultaneously blocking EGFR and TGF-β pathways.
What BICARA THERAPEUTICS INC does
Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors. Its lead candidate, ficerafusp alfa, is an EGFR-directed monoclonal antibody fused to a TGF-β ligand trap, designed to enhance tumor-site drug delivery while minimizing systemic toxicity. The company is primarily testing this candidate in head and neck squamous cell carcinomas.
Themes: oncology / cancer therapy, bifunctional protein engineering, EGFR inhibition, TGF-β pathway modulation, solid tumors, immunotherapy combination treatments
Fundamentals
- Price$17.91 as of 2026-10-21 close
- Market cap$1.2B as of 2026-08-06 (share count; price 2026-10-21)
- 1-year return+5.0% 2025-10-21 close $17.06 → 2026-10-21 close $17.91
- P/En/a negative earnings
- ROE-34.4% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Beta1.44 as of 2026-09-03
- Last reported earnings2026-08-11 SEC EDGAR Form 8-K (Item 2.02)
How BCAX compares in its sector
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | -$60M | -$55M | -$0.82 | -$44M† | $60000† |
| Q1 FY2026 2026-03-31 | -$60M | -$56M | -$0.93 | -$38M | $60000 |
| Q4 FY2025 2025-12-31 | -$41M† | -$37M† | -$0.68† | -$24M† | $238000† |
| Q3 FY2025 2025-09-30 | -$41M | -$36M | -$0.67 | -$29M† | $42000† |
| Q2 FY2025 2025-06-30 | -$32M | -$27M | -$0.50 | -$26M† | $0† |
| Q1 FY2025 2025-03-31 | -$42M | -$37M | -$0.68 | -$28M | $0 |
| Q4 FY2024 2024-12-31 | -$27M† | -$21M† | $7.22† | -$30M† | $40000† |
| Q3 FY2024 2024-09-30 | -$21M | -$17M | -$1.60 | -$17M† | $8000† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$97M
- Short-term investments$401M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How BICARA THERAPEUTICS INC looks technically
BICARA THERAPEUTICS INC (BCAX) is trading 15.2% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 248 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 39, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 42, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 7 trading days ago (its momentum flipped positive). It made a new 20-day low about 11 trading days ago. It is 42.2% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 15.2% below its 200-day average, the long-term trend line — a long-term downtrend | -15.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $21.24 | $21.24 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $21.13 | $21.13 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 13 calendar days ago — the swings before that are what the structure reading is measured on | 13 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 22.26. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible downward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 248 trading days ago — a "golden cross", a bullish long-term signal | 248 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 39, with sellers in control | 39.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 42, neither overbought (above 70) nor oversold (below 30) | 41.9 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($15.85 to $19.12) — its "stochastic" reading is 63 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 63.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 7 trading days ago (its momentum flipped positive) | 7 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $30.99 | $30.99 |
|---|---|---|
| From the 52-week high | it is 42.2% below its 52-week high (its highest price of the past year) | -42.2% |
| Above the 52-week low | it is 30.7% above its 52-week low (its lowest price of the past year) | +30.7% |
| Below the 52-week high | it is 42.2% below its highest point of the past year | 42.2% |
| Since a 20-day breakout | it made a new 20-day low about 11 trading days ago | 11 sessions |
| Since a 55-day breakout | it made a new 55-day low about 11 trading days ago | 11 sessions |
| All-time high | its highest closing price on record is $30.99 (set on 2026-07-07) | $30.99 |
| Given back of the 52-week move | over the past year its closes ranged ($13.93 to $30.40), and it has given back well over two thirds of its rise from last year’s low — 76% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $19.69 to $20.22. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 75.8% |
| From the all-time high | it is 42.2% below its all-time high | -42.2% |
| Nearest price level | it is trading 1.5% above a support level at $17.64 — a price it turned at four times since 2024-11-21, most recently on 2026-03-30. Since 2024-10-21 it has 7 such levels below the current price and 7 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.5% |
| All-time low | its lowest closing price on record is $7.80 (set on 2025-05-23) | $7.80 |
| Above the all-time low | it is 129.6% above its all-time low | +129.6% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 34th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.07 between its high and its low — about 6.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.07 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $16.09 and $19.50 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $16.09 – $17.80 – $19.50 |
| Typical daily range (% of price) | its price moves about 6.0% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.0% |
| Stretch from the 200-day average | it is trading 3.0 daily ranges below its 200-day average price (15.2% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.0 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.83× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 6 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 6 sessions ago |
|---|---|---|
| Since a bullish engulfing | 9 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 9 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-21 0.2% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.2% |
|---|---|---|
| Open gap | it gapped 17.8% below the previous close 50 sessions ago and has not traded back through the level it left behind at 27.73 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -17.8% |
| Gap filled | a 2.3% gap down opened on 2026-09-08 has been "filled" 31 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 31 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 18.6 percentage points (the stock lost 18.6% while the market lost 0.1%) | -18.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 39.7 percentage points (the stock lost 36.4% while the market gained 3.3%) | -39.7% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 32.3 percentage points (the stock lost 22.5% while the market gained 9.8%) | -32.3% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 10.2 percentage points (the stock gained 5.0% while the market gained 15.2%) | -10.2% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, MACD momentum is positive — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 26% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-15 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 12.9% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -26.4% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 18% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $21.73 — a volume-weighted average of daily closes over 192 sessions, not a true tick-by-tick VWAP. | -17.6% |
|---|---|---|
| Vs the average paid since it last reported | the price is 14% below the average price paid since it last reported on 2026-08-11 (its 10-Q), so the typical buyer over that stretch is under water. That average is $20.72 — a volume-weighted average of daily closes over 51 sessions, not a true tick-by-tick VWAP. | -13.6% |
Price levels it has turned at before
BCAX last closed at $17.91 on 2026-10-21. Since 2024-10-21 it has turned at 7 prices below its last close and 7 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $17.64 | Support | 1.5% below the last close | turned there four times · 2024-11-21 to 2026-03-30 |
| $18.32 | Resistance | 2.3% above the last close | turned there twice · 2026-01-09 to 2026-01-22 |
| $16.78 | Support | 6.3% below the last close | turned there twice · 2025-03-07 to 2025-12-02 |
| $19.71 | Resistance | 10.1% above the last close | turned there three times · 2024-12-26 to 2025-12-11 |
| $16.09 | Support | 10.2% below the last close | turned there twice · 2024-12-20 to 2025-04-23 |
| $22.23 | Resistance | 24.1% above the last close | turned there twice · 2024-11-29 to 2026-09-08 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $22.26.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $17.83 and $20.04 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close below $15.85.
This reading has stood for 5 trading days, since 2026-10-15.
Read from daily closes as of 2026-10-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Pulled back from the 12-month high · lagging the market · Most volatile (6%+ typical daily range) · Under water since its last earnings report (below the anchored VWAP) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.36 mean, 1=Strong Buy…5=Strong Sell) — 12 analysts
- Mean price target$35.50 range $20.00 – $45.00
Analyst estimates, as of 2026-10-20. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for BCAX
- Consensus EPS estimate-$0.8217 next reporting period, as of 2026-10-20
- Estimate change, 30 days-$0.0009 from -$0.8208, on 2026-09-15, 35-day window
- Readings revised upward11% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Heavy reliance on the success of a single lead clinical candidate, ficerafusp alfa.","Significant clinical, regulatory, and commercialization risks typical of a clinical-stage biotech without marketed products.","Potential for failure or delay in ongoing Phase 2/3 clinical trials."]
What changed in the latest 10-Q
AI-assisted comparison of BCAX's 10-Q filed 2026-08-11 against the prior one filed 2026-05-11.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-11) states: In August 2026, the company announced the initiation of FORTIFI-FLEX, a randomized clinical study evaluating ficerafusp alfa in combination with pembrolizumab, administered as a 12-week loading dose of 1500mg QW followed by maintenance dosing of 2250mg every three weeks.
- Newer filing (2026-08-11) states: The company expects to have results from the FORTIFI-FLEX study by the time of potential U.S. accelerated approval in 1L R/M HPV-negative HNSCC.
- Newer filing (2026-08-11) states: For the Phase 1b expansion cohorts in 1L R/M HPV-negative HNSCC, the company presented extended follow-up data out to three years at the 2026 American Society of Clinical Oncology Annual Meeting, with the data as of the March 31, 2026 data snapshot showing deep, durable responses driven by TGF-β inhibition.
- Newer filing (2026-08-11) states: All three dose cohorts (750mg QW, 1500mg QW, 2000mg Q2W) demonstrated clinically meaningful duration of response, progression-free survival, and overall survival, plus a generally well-tolerated safety profile.
- Newer filing (2026-08-11) states: Three-year follow-up from the 1500mg QW dose cohort showed an estimated overall survival rate of 31%, approximately doubling the survival rate observed in retrospective analysis with standard of care pembrolizumab in HPV-negative patients.
- Newer filing (2026-08-11) states: Biomarker analyses across all three dose cohorts demonstrated sustained TGF-β inhibition and immune activation with ficerafusp alfa.
- Newer filing (2026-08-11) states: Across a pooled cohort analysis, two-thirds of responders achieved deep responses of greater than 80% tumor shrinkage and experienced more durable disease control, with meaningfully longer DOR, PFS, and OS compared to patients with partial responses of less than 80% tumor shrinkage.
- Newer filing (2026-08-11) renames the bullet '1500mg QW in other solid tumors' (older filing had '1500mg QW plus pembrolizumab in other solid tumors').
- Newer filing (2026-08-11) states: The company expects to present data from the Phase 1b expansion cohorts in other solid tumors in the second half of 2026.
- Removed:
- Older filing (2026-05-11) states: The company planned to initiate the alternate dose study in the third quarter of 2026 based on recent discussions with the FDA.
- Older filing (2026-05-11) states: The company expected to have results from the alternate dose study in time for potential U.S. accelerated approval.
- Older filing (2026-05-11) states: A peer-reviewed manuscript was published in the Journal of Clinical Oncology detailing results from the Phase 1b expansion cohort evaluating 1500mg of ficerafusp alfa QW in combination with pembrolizumab in 1L HPV-negative R/M HNSCC, most recently presented as an oral session at the 2025 ASCO Annual Meeting.
- Older filing (2026-05-11) states: As of the March 20, 2025 data snapshot, the data demonstrated deep and durable responses with prolonged survival, evidenced by a median overall survival of 21.3 months.
- Older filing (2026-05-11) states: The results suggest that ficerafusp alfa facilitated tumor penetration of immune cells by modulating EGFR/TGF-β in the tumor microenvironment.
- Older filing (2026-05-11) states: At the upcoming 2026 ASCO Annual Meeting, the company planned to present three-year follow-up data from the 1500mg QW cohort and longer-term endpoints from the 750mg QW and 2000mg Q2W datasets.
- Older filing (2026-05-11) contains a bullet on Chief Medical Officer transition and appointment of Chief Commercial Officer on May 8, 2026.
- Older filing (2026-05-11) states the company expected to present data from the other solid tumors cohorts in the second half of 2026, in a separate sentence.
- Reworded:
- Newer filing (2026-08-11) describes the alternate dose study update as having been initiated ('we announced the initiation of FORTIFI-FLEX') and names the study FORTIFI-FLEX, whereas the older filing (2026-05-11) described it as a planned study to be initiated in the third quarter of 2026 without the FORTIFI-FLEX name.
- Newer filing (2026-08-11) reframes the February 2026 Phase 1b data presentation as supporting plans to develop an alternate dosing regimen to expand optionality; the older filing (2026-05-11) described the same data and plans without the FORTIFI-FLEX initiation context.
- Newer filing (2026-08-11) changes the cohort bullet heading for other solid tumors from '1500mg QW plus pembrolizumab in other solid tumors' to '1500mg QW in other solid tumors'.
- Notes:
- The provided newer source text appears truncated at the end, cutting off mid-sentence in the Phase 1b expansion cohort section for other solid tumors.
- The provided older source text appears truncated at the end, cutting off mid-sentence in the Chief Medical Officer transition bullet.
- Only the section of MD&A included in the two source texts is compared; changes in other parts of the filing are not assessed.
Risk Factors
- Added:
- In the newer filing (2026-08-11), the net loss figures were added as $55.4 million and $27.4 million for the three months ended June 30, 2026 and 2025, respectively, and $111.6 million and $64.2 million for the six months ended June 30, 2026 and 2025, respectively.
- In the newer filing (2026-08-11), the revenue status reference date was added as June 30, 2026.
- Removed:
- In the older filing (2026-05-11), the net loss figures were $56.2 million and $36.8 million for the three months ended March 31, 2026 and 2025, respectively, which are not present in the newer filing.
- In the older filing (2026-05-11), the revenue status reference date was March 31, 2026, which is not present in the newer filing.
- Reworded:
- The newer filing (2026-08-11) changed 'any future our product candidates' to 'any of our future product candidates' in the bullet list item about seeking regulatory approvals.
- The newer filing (2026-08-11) changed 'development of any of our product candidate' to 'development of any of our product candidates' (plural) in the paragraph about expenses increasing beyond expectations.
- The newer filing (2026-08-11) includes an additional phrase 'to identify and develop additional product candidates either through internal development or through acqu' at the end of the last paragraph, which is not present in the older filing (2026-05-11); however, the newer text appears truncated and the older text ends abruptly, so this may be due to text truncation rather than a substantive change.
- Notes:
- The newer filing text ends mid-sentence ('...through acqu'), and the older filing text also appears to end abruptly ('...through acqu' in the older is not shown, but the older ends after 'through acqu'), so the comparison of the final paragraph may be incomplete.
- OCRed/scraped text contains spacing anomalies (e.g., 'totale d', 'a nd', 'f or'), but these do not appear to represent substantive changes.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 5 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-17. The 5 days since 2026-10-17 have not been checked yet.
- Last 90 days · read to 2026-10-170 buys · 5 sells ($2M) — 3 selling insiders
- Last 180 days · read to 2026-10-170 buys · 20 sells ($4M) — 4 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-08. Based on Form 4 filings read through 2026-10-17; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about BCAX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding BCAX as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 8,395,964
- Reported value $249,276,163
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 2 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about BCAX's institutional holders → See what each manager we track holds →
Short interest (FINRA)
BCAX had 10,693,490 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
BCAX had 16.2% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 14.2 days to cover at the same settlement.
- Reported short interest (shares) 10,693,490
- Short interest (% of shares outstanding) 16.2%
- Prior settlement (shares) 11,191,724
- Reported change -4.45%
- Days to cover (reported) 14.2
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare BCAX vs…
Frequently asked questions
What does BICARA THERAPEUTICS INC (BCAX) do?
Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors. Its lead candidate, ficerafusp alfa, is an EGFR-directed monoclonal antibody fused to a TGF-β ligand trap, designed to enhance tumor-site drug delivery while minimizing systemic toxicity. The company is primarily testing this candidate in head and neck squamous cell carcinomas.
What sector is BICARA THERAPEUTICS INC (BCAX) in?
BICARA THERAPEUTICS INC (BCAX) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are BICARA THERAPEUTICS INC's (BCAX) competitors?
Notable peers of BICARA THERAPEUTICS INC (BCAX) include Merck, Bristol Myers Squibb, AstraZeneca, Eli Lilly and Amgen. This peer set is informational only — not financial advice.
Is BICARA THERAPEUTICS INC (BCAX) overbought or oversold right now?
BICARA THERAPEUTICS INC (BCAX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 42, in the neutral middle (as of 2026-10-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on BCAX come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.